An update on clinical trials in mesothelioma

Slides:



Advertisements
Similar presentations
Launch Event – 6 th November 2014 Trial Information and Design Isabel Rubie – Trial Manager The NAtional Trial of Tonsillectomy IN Adults: a clinical and.
Advertisements

Malignant Pleural Effusions: Treatment with Indwelling Pleural Catheter Luca Bertolaccini 1, Alessandro Berra 2, Emilpaolo Manno 2, Ferdinando Massaglia.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
AN INTRODUCTION TO PET-CT SCANNING Ray Murphy Chair – MCCN Partnership Group.
A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,
The role of surgery in the management of mesothelioma Mr Martyn Carr Consultant Thoracic Surgeon Liverpool Heart and Chest Hospital.
Mesothelioma. Is a malignant tumour of pleura, usually resulting from asbestos exposure. Asbestos is the major single cause and there is a history of.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Dr A.J.France, Ninewells Hospital, Dundee Lung cancer treatment 2010 © A.J.France 2010.
BTS statement on malignant mesothelioma in the UK, 2007 Thorax 2007 Presentation: R3 黃志宇.
Results Recruitment 507 out of 4417 patients were eligible to take part in the study 131 of them (25.5%) participated in the study Demographics Male-female.
Malignant Pleural Effusion (M.P.E.)
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Melanoma Case Control Protocol Summary The study will assemble and follow up a population based cohort of a total of upto 2000 cutaneous melanoma patients.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Day-case medical thoracoscopy
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
Lung Cancer Research Clinical Research Network South West Peninsula Julie Cunningham Research Delivery Manager Oncology / Haematology / Genetics 1.
Worcester and Wyre Forest Pleural Disease Service Dr. Clare Hooper Consultant Respiratory Physician Worcestershire Acute Hospitals NHS Trust.
Research into Practice Audiology Chemotherapy Ototoxicity Project.
Mesothelioma in the South West Gerry Slade Mesothelioma UK CNS.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
ELIGIBILITY CRITERIA- Summarised
National Clinical Pathway for suspected and confirmed lung cancer:
King’s College Hospital, London, UK
11/11/16 Kirstie Wallace/Hazel Muse Transplant Co-ordinators
BCT Bortezomib Consolidation Trial
SWAG SSG Sarcoma Meeting
SABR Update Breast SSG June 2017.
Melanoma Staging an update
Delivery of systemic therapy in Gloucestershire for NSCLC
Mesothelioma studies within our region – 2016 update Nick Maskell
SWAG SSG Skin Cancer Meeting
The British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomized Interventional TreAtment Trial The BHF SENIOR-RITA.
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
The 100,000 Genomes Project and the West of England Genomic Medicine Centre Brief update and overview provided by Catherine Carpenter-Clawson, Programme.
Current and future research topics
Feasibility Study) PB-PG
SWAG SSG Upper GI Cancer Meeting
SWAG SSG Skin Cancer Meeting Tuesday 22nd May Research Report
Pathway for patients with suspected Breast Cancer
Jeff Macemon Waikato Cardiothoracic Unit
SWAG SSG Haematology and Lymphoma Meeting
SWAG SSG Sarcoma Cancer Meeting
GEMSTONE Educational Case Summary
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
Pathway for patients with suspected Upper GI (OG) Cancer
Satya Shanbhag Waikato Cardiothoracic Unit
SWAG SSG Lung Cancer Meeting
SWAG SSG Skin Cancer Meeting
Pathway for patients with suspected colorectal cancer
2018 National Mesothelioma Audit
LATIN-AMERICAN MULTICENTRE STUDY ON ANTIBIOTIC RESISTANCE OF S
MITO CERV …3…(?) Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer.
How to apply successfully to the NIHR HTA Board?
The STAR-TREC Trial SIV Presentation
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Investigation and Management of Malignant Pleural Mesothelioma
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
SWAG SSG Lung Cancer Meeting
Pathway for patients with suspected Breast Cancer
SWAG Network Breast Cancer Site Specific Group
SYNOPSIS OF THE PROTOCOL
Squamous cell carcinoma pathway update
Airedale NHS Foundation Trust
Presentation transcript:

An update on clinical trials in mesothelioma For the SWAG Network Lung SSG Meeting, 22/05/18 Dr Anna Bibby Post CCT NIHR Research Fellow University of Bristol & North Bristol NHS Trust

Overview Summary of trials currently recruiting at NBT Eligibility TARGET ASSESS-meso TILT MARS2 Meso-TRAP Eligibility Trial processes How to get your patient involved

Randomised controlled trial to compare the diagnostic yield of Positron Emission Tomography Computed Tomography (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy.

Multicentre randomised trial PET vs CT-guided biopsy NIHR RfPB funded 1 o/c - diagnostic accuracy 2 o/c - Time to diagnosis - Number of procedures - Healthcare costs N = 45/78 Closes 30/9/18 Blackpool, Bristol, Glasgow, Gloucester, Newport, Norwich, Oxford, Portsmouth, Sheffield, Stoke-on-Trent In suspected pleural malignancy, following previous negative biopsy

Pleural thickening on CT, suspicious for pleural malignancy INCLUSION CRITERIA Pleural thickening on CT, suspicious for pleural malignancy Previous non-diagnostic pleural biopsy in the past 12 months MDT decision to perform further CT-guided biopsy to pursue a diagnosis EXCLUSION CRITERIA Unsuitable for a CT guided biopsy Inability to co-operate/lie still Uncorrectable coagulopathy Inability to tolerate PTx Severe underlying lung disease (FEV1 < 35%) Pleural thickening not amenable to a radiologically guided biopsy Talc pleurodesis in past 6 mo Other exclusions inc: Unable to give consent Pregnancy or lactation Age <18 years

A prospective obServational cohort Study collecting data on dEmographics, Symptoms and biomarkerS in people with mesothelioma that will provide a resource for future trials

Multicentre pragmatic observational study Funding: Avon Mesothelioma Foundation All-comers with mesothelioma Followed up from diagnosis to death Aims: To explore natural history of disease To describe symptoms & symptom evolution To investigate factors affecting outcomes To provide a resource for biomarker testing N = 23/700 Bristol & Oxford open, Taunton, Leicester & Hywell Dda in set up. Factors affecting outcomes including response to chemotherapy Running until 2027 so we’ve got some time

INCLUSION CRITERIA EXCLUSION CRITERIA Histological, cytological or clinico-pathological diagnosis of MPM, confirmed at MDT Willing & able to comply with study follow up assessments (including at least 1 appointment at a study centre) Able to provide written informed consent EXCLUSION CRITERIA Age <18 years old Unable to give written informed consent Declines ongoing hospital follow up

Meets eligibility criteria Clinical assessment, imaging, blood tests, fluid assessment, PROMS Clinical history inc drainage vols, PROMS, recent bloods/ imaging if appropriate Study assessments alongside clinic appts Able/ willing to continue clinic F/U? NO Option to switch to telephone/ postal F/U Meets eligibility criteria Death or withdrawal from study YES Minimum every 3 months

A Trial of Intra-pleuraL bacterial immuno-Therapy in mesothelioma: A feasibility study using the ‘trial within a cohort’ methodology

Randomised 3-arm feasibility trial Based on “trials within cohorts” design Intra-pleural OK432 vs BCG vs usual care Funded by NIHR DRF Primary outcome – feasibility Secondary outcomes – response rates, survival, PROMS N=1/24 Further 12 months recruitment Talk a bit about immunotherapy

INCLUSION CRITERIA EXCLUSION CRITERIA Pathological diagnosis of MPM & enrolled in ASSESS-meso Functioning IPC in situ or willing (& able) to have one inserted No chemotherapy planned for 4 weeks either side of trial Performance status ≤3 Predicted survival ≥12 weeks EXCLUSION CRITERIA Contra-indication to IPC Trapped lung or heavily loculated effusion Known immunodeficiency or immuno-suppressive medication Intercurrent infection Known allergy to OK432, BCG or penicillin Previous immunotherapy Brain metastases or CNS involvement

Intra-pleural OK432

Mesothelioma and Radical Surgery 2: a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma Mention MARS1

Bristol London, in absentia Bristol Locally Bristol London Locally Potentially eligible patient Bristol Eligibility confirmed by surgical team London, in absentia Consent Bristol 2 cycles of chemotherapy, then CT Locally Randomisation Bristol No surgery (Extended) pleurectomy decortication London Up to 4 cycles of chemotherapy Locally Follow up at 6 weeks, 6 months, 12 months, 18 months & 24 months Bristol

INCLUSION CRITERIA EXCLUSION CRITERIA ≥16 years old Tissue confirmed mesothelioma Disease confined to one hemi-thorax on CT Disease deemed surgically resectable Fit for surgery Able to provide written informed consent EXCLUSION CRITERIA Severe shortness of breath PS ≥ 2 Pre-operative FEV1 or TLco <20% Serious concomitant disorder that would preclude surgery Severe heart failure (EF <30%) End stage kidney failure on dialysis Liver failure Prisoner Lacks capacity to consent Enrolled in another interventional trial Nb no staging

Meso-TRAP A study comparing video-assisted thoracoscopic partial pleurectomy/decortication (VATS-PP) with indwelling pleural catheter (IPC) in patients with trapped lung due to malignant pleural mesothelioma Randomised feasibility study Patients have to have “clinically significant trapped lung requiring intervention” Must be fit enough & willing to undergo VATS-PP N=4/38 Aiming to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial in the opinion of the clinical team

How do I get my patient into a trial? All patients discussed at NBT Mesothelioma MDT are screened for eligibility All patients seen in NBT pleural/meso clinic are screened We are happy to receive referrals asking re trial eligibility Also happy to discuss any potentially eligible patients over the phone

Conclusion Meso trials are available at (almost) every step of the patient pathway TARGET ASSESS-meso TILT MARS2 Meso-TRAP All require the patient to travel to Bristol at least once But some treatments can be given locally to reduce travel burden Prof Maskell & I are always happy to discuss potential patients prior to referral Diagnostic Observational Immunotherapy Surgery

Thank you very much Any questions? Anna.Bibby@nbt.nhs.uk Nick.Maskell@bristol.ac.uk Tel: 0117 414 8049 Mob: 07724912367